Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose Cytarabine vs High-dose Daunorubicin in AML Induction
NCT03507842Phase 3Enrolling by invitation
- Sponsor
- Asan Medical Center
- Start
- Mar 2018
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in acute myeloid leukemia (AML) comparing High-dose cytarabine with High-dose daunorubicin (2 arms). Primary endpoint: Cumulative incidence of relapse at 3 years. Started Mar 2018; status: enrolling by invitation.
02
Drugs
cytarabinedaunorubicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03507842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03507842.